Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:42 PM
Ignite Modification Date: 2025-12-25 @ 3:11 PM
NCT ID: NCT01707368
Description: None
Frequency Threshold: 0
Time Frame: 1 year
Study: NCT01707368
Study Brief: Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
All Eligible Patients Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance. 2 None 3 561 50 561 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Psoriasis NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (17.0) View
Colon Cancer NON_SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA (17.0) View
Sudden death NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Flushing NON_SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (17.0) View
Rosacea NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (17.0) View
Abdominal pain NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Respiratory distress NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (17.0) View
Drug ineffective NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Psoriasis NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (17.0) View
Application site pustules NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (17.0) View
Abdominal distension NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Sense of oppression NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Throat tightness NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (17.0) View
Follikulitis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (17.0) View
Application site dryness NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Nausea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View